This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

21 Apr 2011

Elan Reports Profit of $68.2M in Q1

Elan has reported total revenue of $313m for the first quarter ended 31 March 2011.

Irish drug company Elan released results yesterday for the first quarter of its financial year.


Tysabri revenues were up 23% to $245.2 million in the quarter, offsetting revenue loss from legacy products including Azactam, Prialt, Maxipime and Skelaxin, which contributed $38.7 million in 1Q10. Total revenue from the Elan Drug Technologies drug delivery business was $65.9 million (-14%). Earnings in the quarter include a $78.0 million settlement gain related to Abraxis.


1Q Revenues: $313.0 million (+1%)


1Q Earnings: $68.2 million (loss of $6.8 mill

Related News